New Dotarem MRI Contrast

2018 GFR NO LONGER NECESSARY FOR DOTAREM CONTRAST MRI

AT ALL PRINCETON RADIOLOGY PRIVATE IMAGING OFFICES

Princeton Radiology is dedicated to providing the safest and most accurate imaging for your diagnostic needs. To that end, we have recently changed the gadolinium-based contrast agent (GBCA) that is used throughout our practice for Dotarem contrast MRI studies.

After extensive research and review, Princeton Radiology has selected Dotarem® (gadoterate meglumine) as our GBCA of choice. Dotarem is the only macrocyclic and ionic gadolinium-based contrast agent available in the United States and demonstrates the highest intrinsic stability and lowest retention with excellent diagnostic characteristics.

Dotarem has been approved by the US Food and Drug Administration for intravenous use in pediatric patients under two years old, including term neonates. Dotarem is approved in 79 countries worldwide and more than 65 million doses have been administered since it was first launched. There have been no unconfounded cases of nephrogenic systemic fibrosis reported for Dotarem.

Dotarem is the only macrocyclic and ionic gadolinium-based contrast agent available in the United States and demonstrates the highest intrinsic stability and lowest retention with excellent diagnostic characteristics.

DOTAREM is a gadolinium-based contrast agent indicated: for intravenous use. with magnetic resonance imaging (MRI) in brain (intracranial), spine and. associated tissues in adult and pediatric patients (including term neonates) to. detect and visualize areas with disruption of the blood brain barrier (BBB)

Assessment of renal function prior to contrast enhanced MRI studies is no longer required due to Dotarem’s stability and low retention.

Princeton Radiology will continue to assess advancements in GBCA’s and modify clinical practice accordingly as new data becomes available.

Please do not hesitate to contact us if you have any questions or concerns.

Sincerely,

Princeton Radiology Associates, P.A.